Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Finland
  4. Nasdaq Helsinki
  5. Orion Oyj
  6. Summary
    ORNBV   FI0009014377

ORION OYJ

(ORNBV)
  Report
Delayed Quote. Delayed Nasdaq Helsinki - 09/24 11:29:51 am
35.27 EUR   +0.80%
09/17ORION OYJ : President, CEO To Retire In 2022
MT
09/17ORION OYJ : Successor plan of the President and CEO of Orion
AQ
09/17Timo Lappalainen to Retire as CEO of Orion Corporation in 2023
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Helsinki
09/20/2021 09/21/2021 09/22/2021 09/23/2021 09/24/2021 Date
34.49(c) 34.76(c) 34.49(c) 34.99(c) 35.27(c) Last
424 740 360 334 297 776 305 302 359 271 Volume
+0.50% +0.78% -0.78% +1.45% +0.80% Change
More quotes
Estimated financial data (e)
Sales 2021 1 027 M 1 204 M 1 204 M
Net income 2021 200 M 234 M 234 M
Net cash position 2021 171 M 200 M 200 M
P/E ratio 2021 25,4x
Yield 2021 4,18%
Sales 2022 1 070 M 1 254 M 1 254 M
Net income 2022 214 M 250 M 250 M
Net cash position 2022 160 M 187 M 187 M
P/E ratio 2022 23,5x
Yield 2022 4,28%
Capitalization 4 960 M 5 808 M 5 813 M
EV / Sales 2021 4,66x
EV / Sales 2022 4,49x
Nbr of Employees 3 447
Free-Float 88,4%
More Financials
Company
Orion is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows: - generic, OTC and biosimilar drugs (46.3%); - patented prescription products (38.6%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments; - animal products (8.2%); - pharmaceutical ingredients (5.2%); - other (1.7%):... 
Sector
Pharmaceuticals
Calendar
10/20Earnings Release
More about the company
Ratings of Orion Oyj
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about ORION OYJ
09/17ORION OYJ : President, CEO To Retire In 2022
MT
09/17ORION OYJ : Successor plan of the President and CEO of Orion
AQ
09/17Timo Lappalainen to Retire as President of Orion Corporation in 2023
CI
09/17Timo Lappalainen to Retire as CEO of Orion Corporation in 2023
CI
09/14ORION OYJ : 90,889 Orion Corporation A shares converted into B shares
AQ
08/25ORION CORPORATION : Managers' transactions – Kari Jussi Aho
AQ
08/19BIOSTOCK : Alligator Bioscience enters collaboration with Orion Corporation
AQ
08/18ALLIGATOR BIOSCIENCE : announces Immuno-oncology Research Collaboration and License Agreem..
AQ
08/18ORION OYJ : Corporation and Alligator Bioscience announce immuno-oncology research collabo..
AQ
08/18Orion Corporation and Alligator Bioscience Announce Immuno-Oncology Research Collaborat..
CI
08/17ORION OYJ : will remain as the owner of pharmaceutical manufacturing plant in Kuopio, Finl..
AQ
08/03ORION OYJ : Secures Contract To Market, Distribute Marinus' Ganaxolone
MT
08/03ORION OYJ : Corporation signs European wide marketing and distribution agreement with Mari..
AQ
07/23ORION CORPORATION : Managers' transactions – Liisa Hurme
AQ
07/21ORION CORPORATION : Disclosure Under Chapter 9 Section 10 of the Securities Market Act (Bl..
PU
More news
News in other languages on ORION OYJ
09/17Le président-directeur général d'Orion prendra sa retraite en 2022
02/2540 femmes d’affaires qui comptent en Europe
2020Les actions hésitantes, la Chine et les résultats en soutien
2019AVIS D'ANALYSTES DU JOUR : Natixis, BNP Paribas, Kering, Coface, Haulotte, Maersk, Logitec..
2019ORION OYJ : Jefferies fait plier le titre
More news
Analyst Recommendations on ORION OYJ
More recommendations
Chart ORION OYJ
Duration : Period :
Orion Oyj Technical Analysis Chart | ORNBV | FI0009014377 | MarketScreener
Technical analysis trends ORION OYJ
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 6
Last Close Price 35,27 €
Average target price 34,70 €
Spread / Average Target -1,62%
EPS Revisions
Managers and Directors
Timo Antero Lappalainen President & Chief Executive Officer
Jari Ilmari Karlson Chief Financial Officer & SVP-Animal Health
Erkki Mikael Silvennoinen Chairman
Sinikka Markkula Chief Information Officer
Paula Rytilń Chief Medical Officer & Vice President
Sector and Competitors
1st jan.Capi. (M$)
ORION OYJ-6.02%5 808
JOHNSON & JOHNSON4.44%432 675
ROCHE HOLDING AG10.16%321 605
PFIZER, INC.19.37%246 358
NOVO NORDISK A/S50.45%231 485
ELI LILLY AND COMPANY37.22%210 037